Searching for a cure, Improving lives
The FDA have indicated that further discussion with Sarepta “will be necessary to determine what would constitute a complete New Drug Application”. Based on these requests, Sarepta plans to submit an NDA by mid-year 2015, pending any additional requests from further discussions with the FDA. For more information click here.
On the 17th October, Action Duchenne’s CEO Paul Lenihan was asked to appear on ITV News to provide further background to Carl Tilson’s discussions with Summit plc. Paul emphasised throughout his interview that Action Duchenne is committed to early and free access to all new Duchenne medicines regardless of funding and cost and that all